Therefore, one strategy of tumor immunotherapy relies on using anti-PD-1 or anti-PD-L1 monoclonal antibodies to antagonize the targeted molecules of corresponding immune checkpoint, thus restoring T-cell cytotoxic activity against tumor cells. The gene discussed is PDCD1; the disease is neoplasm.